Traumatic Brain Injury - Pipeline Review, H1 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2017" report to their offering.

Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 3, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Traumatic Brain Injury Overview
  3. Therapeutics Development
  4. Pipeline Products for Traumatic Brain Injury - Overview
  5. Pipeline Products for Traumatic Brain Injury - Comparative Analysis
  6. Traumatic Brain Injury - Therapeutics under Development by Companies
  7. Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes
  8. Traumatic Brain Injury Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Traumatic Brain Injury - Products under Development by Companies
  13. Traumatic Brain Injury - Products under Investigation by Universities/Institutes
  14. Traumatic Brain Injury - Companies Involved in Therapeutics Development
  • ALSP Inc
  • Amarantus Bioscience Holdings Inc
  • Apollo Endosurgery Inc
  • Athersys Inc
  • Beech Tree Labs Inc
  • Cognosci Inc
  • Eustralis Pharmaceuticals Ltd
  • Intellect Neurosciences Inc
  • International Stem Cell Corp
  • Ischemix Inc
  • Karyopharm Therapeutics Inc
  • Kyorin Pharmaceutical Co Ltd
  • Levolta Pharmaceuticals Inc
  • Lixte Biotechnology Holdings Inc
  • MandalMed Inc
  • Mapreg SAS
  • Neuralstem Inc
  • Neuren Pharmaceuticals Ltd
  • Neurofx Inc
  • NeuroNascent Inc
  • NeuroVive Pharmaceutical AB
  • New World Laboratories Inc
  • NuvOx Pharma LLC
  • Omeros Corp
  • Oxeia Biopharmaceuticals Inc
  • PharmatrophiX Inc
  • Phylogica Ltd
  • Prevacus Inc
  • STATegics Inc
  • Stemedica Cell Technologies Inc
  • SynZyme Technologies LLC
  • Tetra Discovery Partners LLC
  • Thera Neuropharma Inc
  • vasopharm GmbH
  • VG Life Sciences Inc

For more information about this report visit http://www.researchandmarkets.com/research/wspw57/traumatic_brain

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs